
Liminal BioSciences LMNL
Quartalsbericht 2022-Q2
hinzugefügt 10.08.2022
Liminal BioSciences DPO 2011-2026 | LMNL
DPO Jährlich Liminal BioSciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.64 K | 1.39 K | - | - | - | - | - | 260 | 164 | - |
Alle Zahlen in CAD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.64 K | 164 | 864 |
DPO anderer Aktien in der Pharmaeinzelhändler
| Name | DPO | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | ||
|
Alnylam Pharmaceuticals
ALNY
|
55 | $ 326.56 | -2.05 % | $ 42.8 B | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
31.7 | $ 21.48 | -0.92 % | $ 1 B | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
1.83 K | - | -5.16 % | $ 5.39 M | ||
|
Akebia Therapeutics
AKBA
|
168 | $ 1.41 | -9.12 % | $ 363 M | ||
|
Aquestive Therapeutics
AQST
|
395 | $ 4.16 | -1.89 % | $ 445 M | ||
|
Arcutis Biotherapeutics
ARQT
|
133 | $ 24.22 | -1.46 % | $ 3.08 B | ||
|
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.48 | -0.67 % | $ 394 M | ||
|
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B | ||
|
Caladrius Biosciences
CLBS
|
51.2 | - | -16.75 % | $ 25.8 M | ||
|
Clearside Biomedical
CLSD
|
1.67 K | - | - | $ 25.3 M | ||
|
Celldex Therapeutics
CLDX
|
4.06 K | $ 33.53 | -1.0 % | $ 2.23 B | ||
|
bluebird bio
BLUE
|
182 | - | - | $ 546 M | ||
|
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B |